Nonlinear pharmacokinetics of piperacillin in healthy volunteers - implications for optimal dosage regimens

British Journal of Clinical Pharmacology

Volumn 70, Issue 5, 2010, Pages 682-693

  Bulitta, Jürgen B ^a,e   Kinzig, Martina ^a   Jakob, Verena ^a   Holzgrabe, Ulrike ^b   Sörgel, Fritz ^a,c   Holford, Nicholas H G ^d  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Healthy volunteers; Monte Carlo simulation; Piperacillin population pharmacokinetics pharmacodynamics; Saturable elimination; Within subject variability between occasion variability

Indexed keywords

PIPERACILLIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MODELS, STATISTICAL; MONTE CARLO METHOD; PIPERACILLIN; YOUNG ADULT;

EID: 78649275432     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03750.x     Document Type: Article

References (77)

1. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 1998; 20: 149-60.
2. Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48: 4718-24.
3. Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 2003; 47: 541-7.
4. Bergan T. Overview of acylureidopenicillin pharmacokinetics. Scand J Infect Dis Suppl 1981; 29: 33-48.
5. Aronoff GR, Sloan RS, Brier ME, Luft FC. The effect of piperacillin dose on elimination kinetics in renal impairment. Eur J Clin Pharmacol 1983; 24: 543-7.
6. Batra VK, Morrison JA, Lasseter KC, Joy VA. Piperacillin kinetics. Clin Pharmacol Ther 1979; 26: 41-53.
7. Bergan T, Williams JD. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 1982; 28: 153-9.
8. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 1978; 14: 829-37.
9. Morrison JA, Batra VK. Pharmacokinetics of piperacillin sodium in man. Drugs Exp Clin Res 1979; 5: 105-10.
10. Evans MAL, Leung T, Wilson P, Williams JD. Pharmacokinetics of intravenously administered antibiotics: a study of piperacillin, a new semi-synthetic penicillin. Drugs Exp Clin Res 1979; 5: 111-16.
11. Evans MA, Wilson P, Leung T, Williams JD. Pharmacokinetics of piperacillin following intravenous administration. J Antimicrob Chemother 1978; 4: 255-61.
12. Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, Faulkner R, Dutta A, Haynes J, Greene DS, Kuye O. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992; 51: 32-41.
13. Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 1997; 41: 2511-7.
14. Reed MD, Goldfarb J, Yamashita TS, Lemon E, Blumer JL. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994; 38: 2817-26.
15. Sullivan MC, Nightingale CH, Quintiliani R, Sweeney K. Comparison of the pharmacokinetic and pharmacodynamic activity of piperacillin and mezlocillin. Pharmacotherapy 1993; 13: 607-12.
16. Welling PG, Craig WA, Bundtzen RW, Kwok FW, Gerber AU, Madsen PO. Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother 1983; 23: 881-7.
17. Wise R, Logan M, Cooper M, Andrews JM. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 1991; 35: 1081-4.
18. Zaghloul I, Kuck N, Yacobi A. The effect of tazobactam on the pharmacokinetics and the antibacterial activity of piperacillin in dogs. Int J Pharm 1997; 153: 115-21.
19. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005; 56: 388-95.
20. Sorgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993; 31 (Suppl. A): 39-60.
21. Anonymous. Piperacillin sodium and tazobactam sodium (Zosyn) product information. Lederle Laboratories, Pearl River, N.Y. Revised 5 April 1999.
22. Eagle H, Fleischman R, Musselman AD. The effective concentrations of penicillin in vitro and in vivo for streptococci, pneumococci, and Treponema pallidum. J Bacteriol 1950; 59: 625-43.
23. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-83.
24. Kirby WM. Bacteriostatic and lytic actions of penicillin on sensitive and resistant staphylococci. J Clin Invest 1945; 24: 165-69.
25. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
26. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
27. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
28. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-9.
29. Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 1990; 74: 179-84.
30. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-92.
31. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998; 35: 391-402.
32. Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? - efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38: 5-15.
33. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36: S42-50.
34. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003; 52: 518-21.
35. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-23.
36. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004; 26: 493-501.
37. Mouton JW, Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother 1991; 28: 911-8.
38. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43: 523-7.
39. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999; 43: 309-11.
40. Lemmen SW, Engels I, Daschner FD. Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers. J Antimicrob Chemother 1997; 39: 841-2.
41. Mouton JW, Horrevorts AM, Mulder PG, Prens EP, Michel MF. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990; 34: 2307-11.
42. Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996; 40: 61-4.
43. Daenen S, Erjavec Z, Uges DR, De Vries-Hospers HG, De Jonge P, Halie MR. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995; 14: 188-92.
44. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996; 40: 691-5.
45. Richerson MA, Ambrose PG, Bui KQ, Grant E, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered either as continuous or intermittent infusion with once-daily gentamicin. Infect Dis Clin Pract 1999; 8: 195-200.
46. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22: 471-83.
47. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
48. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13: 598-606.
49. Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008; 14: 390-6.
50. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 122-6.
51. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284: 1677-9.
52. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-32.
53. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32.
54. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-507.
55. Brendel K, Comets E, Laffont C, Laveille C, Mentre F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006; 23: 2036-49.
56. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66.
57. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
58. Beal SL, Boeckmann AJ, Sheiner LB, NONMEM Project Group. NONMEM Users Guides, Version 5 edition. San Francisco, CA: University of California at San Francisco, 1999.
59. Bauer RJ. S-ADAPT/MCPEM User's Guide (Version 1.55). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA, 2007.
60. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.
61. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guides. Ellicott City, Maryland, USA: Icon Development Solutions, 2006. 1989-2006.
62. Bulitta JB, Landersdorfer CB, Kinzig M, Holzgrabe U, Sorgel F. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics. Antimicrob Agents Chemother 2009; 53: 3462-71.
63. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
64. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
65. Bulitta JB, Holford NHG. Assessment of Predictive Performance of Pharmacokinetic Models Based on Plasma and Urine Data. Brisbane, Qld: PAGANZ - Population Approach Group in Australia & New Zealand, 2005.
66. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45: 13-22.
67. Sorgel F, Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 1994; 20 (Suppl. 3): S14-20.
68. Grahnen A, Hammarlund M, Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 1984; 27: 595-602.
69. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 1999; 48: 9-13.
70. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis - bolus versus continuous administration? Crit Care Med 2009; 37: 926-33.
71. Eagle H. The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum. J Exp Med 1949; 90: 595-607.
72. Lee D, Murakami Y, Stamstad T, Marchillo K, Ashbeck J, Andes DR, Craig WA. Inoculum Effect of Daptomycin (D), Linezolid (L), Vancomycin (V), and Ceftobiprole (C) with Staphylococcus aureus (SA) and Streptococcus pneumoniae (SP) in Neutropenic Mice at 105 and 107 CFU in Opposite Thighs. In: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abst A-37, Chicago, IL, 2007.
73. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167: 1401-5.
74. Hope WW, Drusano GL, Moore CB, Sharp A, Louie A, Walsh TJ, Denning DW, Warn PA. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob Agents Chemother 2007; 51: 285-95.
75. Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51: 3510-5.
76. Mouton JW, Punt N. Use of the t >MIC to choose between different dosing regimens of beta-lactam antibiotics. J Antimicrob Chemother 2001; 47: 500-1.
77. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 2007; 27: 1490-7.